Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-12-30
2008-09-02
Vivlemore, Tracy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A, C536S025300
Reexamination Certificate
active
07420050
ABSTRACT:
The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-β.
REFERENCES:
patent: 5683874 (1997-11-01), Kool
patent: 2002/0182586 (2002-12-01), Morris et al.
patent: 1239034 (2002-09-01), None
patent: WO 00/61595 (2000-10-01), None
patent: WO 00/61595 (2000-10-01), None
Han et al. Therapy with antisense TGF-B1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Apr. 2000. American Journal of Physiology-Renal Physiology. vol. 278. pp. F628-634.
Spearman et al. Antisense oligodeoxyribonucleotide inhibition of TGF-B1 gene expression and alterations in the growth and mailgnant properties of mouse fibrosarcoma cells. 1994. Gene. vol. 149. pp. 25-29.
Moon et al. Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1. Feb. 2000. Journal of Biological Chemistry. vol. 275. pp. 4647-4653.
Fakhrai et al. Eradicatioin of established intracranial rat gliomas by transforming growth factor.beta. antisense gene therapy. Apr. 1996. Proceedings of the National Academy of Sciences, USA vol. 93 pp. 2909-2914.
Moon et al., “Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb”, Biochem. J., 2000, 346: 295-303.
Futaki et al., “Arginine-rich Peptides”, The Journal of Biological Chemistry, 2001, 276(8): 5836-40.
Efthymiadis et al., “The HIV-1 Tat Nuclear Localization Sequence Confers Novel Nuclear Import Properties”, The Journal of Biological Chemistry, 1998, 273(3): 1623-8.
Wu et al., “TGF-Beta1 is an Autocrine-negative Growth Regulator of Human Colon Carcinoma FET Cells in vivo as Revealed by Transfection of an Anitsense Expression Vector”, The Journal of Cell Biology, 1992, 116(1): 187-96.
Fitzpatrick et al., “Transforming Growth Factor-Beta:Antisense RNA-Mediated Inhibition Affects Anchorage-Independent Growth, Tumorigenicity and Tumor-Infiltrating T-Cells in Malignant Mesothelioma”, Growth Factors, 1994, 11: 29-44.
Maggard et al., “Antisense TGF-Beta2 Immunotherapy for Hepatocellular Carcinoma: Treatment in a Rat Tumor Model”, Annals of Surgical Oncology, 2001, 8(1): 32-7.
Akagi et al., “Inhibition of TGF-Beta1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis,” Kidney International, 50: 148-155 (1996).
Choi et al., “Prevention of tissue injury by ribbon antisense to TGF-Beta1 in the kidney,” International Journal of Molecular Medicine, 15: 391-399 (2005).
Isaka, Y., “Application of gene therapy to kidney diseases,” Clin Exp Nephrol, 3: 147-153 (1999).
Isaka et al., “Transforming growth factor-Beta1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction,” Kidney International, 58: 1885-1892 (2000).
Ando et al., “Introduction of TGF-beta antisense oligodeoxy-nucleotides (ODN) into interstitial fibroblast blocked tubulointerstitial fibrosis in unilateral ureter obstruction (UUO) rats,” Journal of Americal Society of Nephrology, 9: 512A (1998), abstract A2617.
Isaka Y et al., “Transforming growth factor-beta1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction,” Kidney International, 58(5):1885-1892 (2000).
Isaka Y, “Application of gene therapy to kidney diseases,” Clinical and Experimental Nephrology, 3:147-153 (1999).
Ando Y et al., “Introduction of TGF-beta antisense oligodeoxy-nucleotides (ODN) into interstitial fibroblast blocked tubulointerstitial fibrosis in unilateral ureter obstruction (UUO) rats,” Journal of the American Society of Nephrology, 9: 512A (1998).
Akagi Y et al., “Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis,” Kidney International 50(1) 148-155 (1996).
Moon et al., “Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1,” The Journal of Biological Chemistry, 275(7): 4647-4653 (2000).
Moon et al., “Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb,” Biochem. J., 346:295-303 (2000).
Choi Young-Kook
Moon Ik-Jae
Park Jong-Gu
Park Kwankyu
JHK Law
Kim Joseph Hyosuk
Vivlemore Tracy
Welgene Pharmaceuticals, Inc.
LandOfFree
TGF-β-specific covalently closed antisense molecule does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TGF-β-specific covalently closed antisense molecule, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TGF-β-specific covalently closed antisense molecule will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967018